Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
22nd Century (XXII) just unveiled an update.
On June 24, 2024, GVB Biopharma paid $1.5 million towards reducing their outstanding debt to JGB Partners, LP, lowering the total debt to approximately $8.3 million. Additionally, the final half-million-dollar payment has been deferred to December 31, 2024. The company announced this financial milestone in a press release the following day.
For detailed information about XXII stock, go to TipRanks’ Stock Analysis page.